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Summary
A goal of synthetic biology bio-foundries is to inno-
vate through an iterative design/build/test/learn pipe-
line. In assessing the value of new chemical
production routes, the intellectual property (IP) nov-
elty of the pathway is important. Exploratory studies
can be carried using knowledge of the patent/IP
landscape for synthetic biology and metabolic engi-
neering. In this paper, we perform an assessment of
pathways as potential targets for chemical produc-
tion across the full catalogue of reachable chemicals
in the extended metabolic space of chassis organ-
isms, as computed by the retrosynthesis-based algo-
rithm RetroPath. Our database for reactions
processed by sequences in heterologous pathways
was screened against the PatSeq database, a com-
prehensive collection of more than 150M sequences
present in patent grants and applications. We also
examine related patent families using Derwent Inno-
vations. This large-scale computational study pro-
vides useful insights into the IP landscape of
synthetic biology for ﬁne and specialty chemicals
production.
Introduction
Efﬁcient and sustainable microbial production through
cell factory synthetic biology is a promising enabling
technology in the transition from an economy based on
fossil fuels towards an economy based on renewable
biomass resources (SBLC, 2016). The synthetic biology
of ﬁne and speciality chemicals is a biomanufacturing
technology that, by 2020, is envisioned as providing
cheaper economical, predictable and sustainable routes
to an enlarged portfolio of novel, diverse, and previously
expensive products in many sectors including cosmetics,
ﬂavors, polymers, and pharmaceuticals (Carbonell et al.,
2016; Breitling and Takano 2016). A roadmap to com-
mercialization of such products will need to both inte-
grate and navigate the scientiﬁc and technological
knowledge accumulated in patents into the biodesign
process, so as to reduce transaction costs and lower the
risk of failure as well as to maximize the innovation cap-
abilities of the synthetic biology pipeline. One reported
estimate suggests that by 2025 bio-production will repre-
sent up to 28% of the global chemical market ($614Bm)
(USDA 2008). Industrial bio-production is nevertheless a
complex process whose analysis requires multi-scale
approaches integrating cell, bioprocess, and ecosystem
models with economic, innovation and policy considera-
tions. Recent advances in metabolic engineering and
synthetic biology have led to an increase in the portfolio
of both key building block chemicals and ﬁne chemicals
that can be microbially produced from biomass feedstock
(Curran and Alper, 2012). Emerging computation plat-
forms for synthetic biology (Carbonell et al., 2016b) in
combination with rapid DNA engineering and assembly
techniques (Casini et al., 2015) are contributing to
streamline metabolic pathway design and strain engi-
neering. Synthetic biology techniques that insert stan-
dardized and characterized genetic parts are used to
regulate and ﬁne-tuning the engineered biosynthetic
pathways in the chassis (Chao et al., 2015). Nowadays,
the establishment of synthetic biology bio-foundries
enables the application of automated design–build–test–
learn cycles to microbial cell factories so that natural
pathways can be refactored and novel reactions and
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products can be discovered (Hara et al., 2014; Carbonell
et al., 2016a).
Yet, despite the increasing number of small molecules
that are bio-produced, the process still remains a com-
plex system, costly and rather slow. For instance, the
metabolic engineering of artemisinic acid is claimed to
have taken over 200 person-years to date (Nielsen and
Keasling, 2016). The challenge of sustainable chemical
production, thus, needs to be addressed not only by
considering the different temporal and spatial scales that
are present in microbial production bioprocesses
(Zhuang et al., 2013), but also by monitoring innovation
(Kahl and Endy, 2013) to deﬁne multi-objective goals
compatible with a more rational use of biomass. Here,
we perform a patent analysis of biosynthetic pathways
for ﬁne chemicals to explore the innovation landscape of
metabolic design for microbial synthetic production. Our
study compared the reachable metabolic space in the
chassis Escherichia coli, based on our current knowl-
edge of enzyme sequences present in biochemical
routes, with the set of sequences disclosed in patents
since 1970 (Jefferson et al., 2015).
Although multiple factors are involved in the success-
ful commercialization of scientiﬁc and technological
knowledge, the accumulation and analysis of intellectual
property (IP) through patenting offers important signals
as to targets that might subsequently have exploitable
value in biotechnology and synthetic biology (Petruzzelli
et al., 2015; see also Bubela et al., 2013). Performing
patent analyses in emerging technologies such as syn-
thetic biology is challenging, as speciﬁc classiﬁcations
are lacking or at best lagging in the international patent
classiﬁcation system. Prior studies (e.g. van Doren et al.,
2013) have attempted to deﬁne synthetic biology patents
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Fig. 1. Incidence of pathways in patent documents per year: (A) frequency of year of ﬁrst occurrence of a pathway in analysed patents; (B)
median of occurrence of the pathway.
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using selected keywords. However, such approaches
face problems of both precision and recall. In this study,
we put forward a novel approach by analysing chemical
pathways. We focus on a speciﬁc type of synthetic biol-
ogy application, that is, expression of chemical pathways
for the production of ﬁne and speciality chemicals in cell
factories. Moreover, we restricted our study to those
cases corresponding to synthetic pathways that are not
naturally produced in the chassis. Non-native biosyn-
thetic pathways are of special interest since the expres-
sion in the heterologous host can be performed through
a full refactoring of the pathway and combinatorial
biosynthesis (Luo et al., 2015). This focused approach
allows us to develop a more ﬁnely tuned search
0 2 4 6 8 10
1
Pathway length
Fr
eq
ue
nc
y
RetroPath
Patents
Fig. 2. Frequency of pathway lengths found in patent documents compared with reachable pathways in Escherichia coli according to Retro-
Path.
Table 1. Number of compounds and their average price found in patent documents in comparison with the reachable metabolic space and
average market price (USD/10 mg) for available compounds.
Class Frequency In path All Top organism Avg. price all Avg. price in path
Lipids 52.40 523 998 Arabidopsis thaliana 429.38 771.64
Carbohydrates 52.50 304 579 A. thaliana 494.19 568.08
Terpenoids 36.06 163 452 A. thaliana 643.06 1709.32
Phenols 46.51 180 387 A. thaliana 109.82 58.30
Hydrocarbons 81.19 246 303 Abies grandis 178.49 255.49
Flavonoids 27.54 76 276 Medicago sativa 273.40 404.81
Alcohols 55.07 152 276 A. thaliana 701.40 1159.63
Ketones 36.60 97 265 M. sativa 244.71 464.80
Amides 55.14 134 243 A. thaliana 70.52 60.98
Benzenes 33.01 69 209 A. thaliana 33.69 52.98
Carboxamides 55.90 109 195 A. thaliana 77.40 60.98
Benzopyrans 25.40 48 189 M. sativa 347.90 388.97
Phenylpropanoids 30.65 57 186 A. thaliana 216.75 269.63
Cyclic ketones 29.17 42 144 M. sativa 267.65 351.17
Diterpenoids 24.82 35 141 Abies balsamea 25.24 25.00
Alkaloids 15.91 21 132 Coffea arabica 41.94 14.14
Monoterpenoids 14.96 19 127 Ocimum basilicum 24.54 25.00
Polyols 53.33 64 120 Homo sapiens 107.02 78.40
Benzenediols 55.46 66 119 Pseudomonas putida 70.87 144.97
Primary alcohols 62.04 67 108 A. thaliana 1117.14 1680.94
Purines 51.61 48 93 A. thaliana 28.11 19.57
Benzopyrroles 72.37 55 76 A. thaliana 34.79 37.00
Sesquiterpenoids 58.11 43 74 Streptomyces avermitilis 2501.44 3717.33
Triterpenoids 61.67 37 60 A. thaliana 129.35 126.20
Monoterpenes 94.83 55 58 A. grandis 19.67 19.67
Hydroxyﬂavanones 58.49 31 53 M. sativa 263.96 351.17
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methodology: we deﬁne our strategy in terms of dis-
closed sequences encoding biosynthetic enzymes that
belong to pathways not present in the chassis rather
than focusing on their chemical targets (Papadatos
et al., 2016). This approach can suffer in some cases
from low precision in instances, where these sequences
are mentioned in the patent for some other reason not
related to bioproduction. Nevertheless, this issue does
not invalidate the basic approach of this study of search-
ing and analysing heterologous pathways in patents
through their associated enzymes. Notably, this synthetic
biology application has been already present in some
form since earlier biotechnology applications such as
genome and metabolic engineering. Hence, we can
assess the impact that the advent of synthetic biology
and engineering biology technologies has exerted in
metabolic design and the development of cell factories,
and also in the associated IP landscape.
Results and discussion
We screened for disclosed sequences in patent docu-
ments since 1970 (Jefferson et al., 2015) that matched
sequences encoding enzymes in biosynthetic pathways
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Fig. 3. Distribution of compounds in patents in the reachable chemical space: (A) chemical space of reachable compounds (blue) highlighting
those compounds whose pathways were found in patent documents (red); (B) chemical space of reachable compounds (blue) and compounds
in patents (red) plotted with a third axis representing pathway length.
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for ﬁne and speciality chemicals in metabolic databases
(Alcantara et al., 2012; Caspi et al., 2012; Moretti et al.,
2016). (See Data S1 for discussion and sources of
patent documents and patent families.) The aim was to
identify cases potentially useful for synthetic biology
applications involving the expression of gene sequences
imported from foreign organisms into a chassis host. Our
reference chassis is E. coli and therefore the study
focused on enzymes that were not natively found in that
chassis.
We traced references to enzyme sequences in
patents to as early as 1988, where we found a refer-
ence in patent WO 1988007079 A1 to the sequence of
a tyrosinase (EC 1.14.18.1) from Streptomyces catalyz-
ing the oxidation of L-tyrosine into L-DOPA (Satoh et al.,
2012). Figure 1A shows the years of ﬁrst occurrence of
pathways in patent documents, with a maximum inci-
dence centred around the year 2002. A different result
emerged when we consider the median year of occur-
rence of each pathway, as shown in Fig. 1B. In this
case, we can see a consistent growth in time in the
number of times that a pathway appears in a patent
document, at least up to 2015. Note that there is a lag
between patent application, publication, and inclusion in
databases, so records for most recent years are not yet
complete.
As anticipated, biosynthetic pathways involving low
number of enzymes have higher incidence in patent doc-
uments than in the full catalogue of pathways amenable
to metabolic engineering, as shown in Fig. 2. We can
expect this result, as the expression and balancing of
heterologous pathways in chassis introduces a metabolic
Table 2. Leading Derwent classiﬁcations of synthetic biology ﬁne chemical patents.
Derwent classiﬁcations (Classes) Number of patents Percentage of all patents
D16 (Fermentation industry) 1990 94%
B04 (Natural products and polymers, testing, compounds of unknown structure) 1100 52%
C06 (Biotechnology, plant genetics, veterinary vaccines) 469 22%
S03 (Scientiﬁc Instrumentation, photometry, calorimetry) 294 14%
E17 (Other aliphatics) 290 14%
P13 (Plant culture, dairy products) 243 11%
D13 (Other foodstuffs and treatment) 230 11%
B05 (Other organics – aromatics, aliphatic, organo-metallics) 179 8%
T01 (Digital Computers) 130 6%
A41 (Monomers, Condensants; see also Section E) 103 5%
Source: own calculation based on the Derwent Innovation Index (DII). N=2,118 patent families with application years= 1993-2016. A patent may
be classiﬁed in more than one Derwent Class, thus totals exceed 100%.
Fig. 4. Number of Patents by Derwent Classes. Source: own calculation based on the Derwent Innovation Index (DII). A patent can be classi-
ﬁed in more than one Derwent Class, thus total exceed 100%.
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burden, among other issues, that often increases with
the number of foreign enzymes that are expressed.
When alternative pathways exist for the production of
the same compound, the ﬁrst choice for a synthetic path-
way may be the shortest one. Therefore, the rate of suc-
cess for the expression of a heterologous pathway
generally decreases with pathway length. In most cases,
a single heterologous pathway was identiﬁed in the
patent document, although in some cases, patent docu-
ments contained enzymes associated with multiple path-
ways (Fig. S1). Similarly, the number of target
compounds that could be produced through the path-
ways found in patent documents was often found to be
higher than one (Fig. S2). However, these numbers are
inﬂuenced by the fact that the presence of one pathway
implies also those pathways producing each heterolo-
gous intermediate across the biosynthetic route. The pre-
vious analysis, thus, reﬂects different perspectives as
both pathways themselves imply the production of inter-
mediates and also multiple alternative pathways may be
available for producing a target compound.
Enumerating all pathways that can produce a target
compound is not trivial, as it requires specialized algo-
rithms. Several techniques exist based on graph theory,
elementary ﬂux modes, minimal cut sets, as well as
others (Carbonell et al., 2012). We have considered here
pathways enumerated by the RetroPath algorithm based
on elementary ﬂux modes (Carbonell et al., 2012, 2014).
Once the total number of alternative pathways has been
determined, several biotechnological considerations can
lead to alternative choices depending on the expected
pathway performance. Several criteria exist for ranking
and pathway selection in addition to pathway length
considerations, including thermodynamics feasibility, the-
oretical yield and enzyme performance (Carbonell et al.,
2016a,b). Furthermore, we consider here that the choice
of a pathway can also be inﬂuenced by its intellectual
property rights protection. Interestingly, we found
cases where the number of alternative pathways per
target compounds found in patent documents went up
to 13 alternative pathways, which implies a high degree
of exploration and innovation in the search for the
Table 3. Leading commercial patenting organizations and Derwent classiﬁcations of their synthetic biology ﬁne chemical patents.
Organization
Number of
patents
Share of
patents in
the dataset
Leading Patent Classes and their share in organization’s
patents in the dataset
DU PONT 88 4.0% 99%: D16 (Fermentation industry)
41%: E17 (Other aliphatics)
32%: C06 (Biotechnology, plant genetics, veterinary vaccines)
BASF 77 3.5% 100%: D16 (Fermentation industry)
70%: C06 (Biotechnology, plant genetics, veterinary vaccines)
53%: P13 (Plant culture, dairy products)
AJINOMOTO 58 2.7% 100%: D16 (Fermentation industry)
62%: B05 (Other organics - aromatics, aliphatic, organo-metallics.)
36%: D13 (Other foodstuffs and treatment)
DSM IP ASSETS 57 2.6% 96%: D16 (Fermentation industry)
36%: D13 (Other foodstuffs and treatment)
33%: B04 (Natural products and polymers, testing, compounds of
unknown structure)
BUTAMAX ADVANCED BIOFUELS 50 2.3% 100%: D16 (Fermentation industry)
75%: E17 (Other aliphatics)
33%: H06 (Gaseous and liquid fuels including pollution control)
BAYER 46 2.1% 91%: D16 (Fermentation industry)
72%: C06 (Biotechnology, plant genetics, veterinary vaccines)
35%: P13 (Plant culture, dairy products)
MITSUI & TORAY 36 1.6% 81%: D16 (Fermentation industry)
38%: E16 (Aliphatics containing N and/or halogem)
31%: B04 (Natural products and polymers, testing, compounds of
unknown structure)
MONSANTO 33 1.5% 97%: D16 (Fermentation industry)
94%: C06 (Biotechnology, plant genetics, veterinary vaccines)
64%: P13 (Plant culture, dairy products)
GOODYEAR TIRE & RUBBER CO 24 1.1% 100%: D16 (Fermentation industry)
58%: E17 (Other aliphatics)
54%: A41 (Monomers, Condensants)
MITSUBISHI 22 1.0% 41%: D16 (Fermentation industry)
18%: T01 (Digital Computers)
14%: B04 (Natural products and polymers, testing, compounds of
unknown structure)
Source: own calculation based on the Derwent Innovation Index (DII). N=2,118 patent families with application years= 1993-2016. A patent is
classiﬁed in more than one Derwent Class, thus totals exceed 100%.
ª 2016 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 9, 687–695
692 P. Carbonell, A. G€ok, P. Shapira and J.-L. Faulon
optimal pathway to produce a desired compound
(Fig. S3).
Our screening for biosynthetic pathways in patent doc-
uments allowed us to gain insights into the landscape of
chemicals of interest. We looked at the percentage of
chemical classes whose biosynthetic pathways were
identiﬁed in the sequence in pathways. We focused on
some of the classes of higher interest. Table 1 provides
a list for the selected classes based on the ChEBI ontol-
ogy (Hastings et al., 2013) sorted by the number of com-
pounds in our dataset of reachable heterologous
compounds. We also looked at the organism whose
sequence appeared more often for each class of com-
pounds. We found, for instance that 36% of terpenoids
appeared in patents and that Arabidopsis thaliana is its
main source organism. Similarly, 15% and 28% of alka-
loids and ﬂavonoids considered as pathway-reachable
were found in patent documents respectively. Their main
sources were Coffea arabica for alkaloids and Medicago
sativa for ﬂavonoids. Looking at the average market
price of available compounds in the selected classes,
we found that terpenoids found in patent documents had
the greatest market value, which was considerable
higher than the overall average market value of these
compounds. (Aldrich Market Select was used to query
market prices by compound chemical structure.) Flavo-
noids in patent documents also had a higher market
value than their average market value, which was the
opposite in the case of alkaloids. These results are help-
ful in informing consideration of the pricing implications
of patented synthetic biology compounds compared with
chemical and natural production. It should be stressed
that this study was focused on compounds for which
biosynthetic pathways are known and their enzyme
sequences reported in databases. This means that the
market values in Table 1 should be updated as long as
novel sequences leading to additional, potentially more
valuable pathways and compounds are discovered.
We also probed the chemical space covered by path-
ways found in patents in comparison with the area cov-
ered by the full reachable chemical space. The main
question was to explore if there were privileged regions
in the reachable space that were enriched in compounds
present in patents, while others had less coverage and
therefore could potentially constitute target compound
classes in terms of innovation. Figure 3A shows the
Table 4. Leading non-commercial patenting organizations and Derwent classiﬁcations of their synthetic biology ﬁne chemical patents.
Organization
Number
of patents
Share of patents
in the dataset Leading Patent Classes and their share in organizations identiﬁed patents
UNIV CALIFORNIA 32 1.5% 97%: D16 (Fermentation industry)
56%: B04 (Natural products and polymers, testing, compounds of unknown structure)
47%: E17 (Other aliphatics)
CNRS 17 0.8% 100%: D16 (Fermentation industry)
76%: B04 (Natural products and polymers, testing, compounds of unknown structure)
23%: C06 (Biotechnology, plant genetics, veterinary vaccines)
TECHNION 12 0.5% 100%: D16 (Fermentation industry)
92%: B04 (Natural products and polymers, testing, compounds of unknown structure)
25%: S03 (Scientiﬁc Instrumentation, photometry, calorimetry)
INSERM 11 0.5% 100%: D16 (Fermentation industry)
91%: B04 (Natural products and polymers, testing, compounds of unknown structure)
27%: S03 (Scientiﬁc Instrumentation, photometry, calorimetry)
UNIV OSAKA 11 0.5% 100%: D16 (Fermentation industry)
91%: B04 (Natural products and polymers, testing, compounds of unknown structure)
18%: S03 (Scientiﬁc Instrumentation, photometry, calorimetry)
HEBREW UNIV
JERUSALEM
10 0.5% 100%: D16 (Fermentation industry)
60%: B04 (Natural products and polymers, testing, compounds of unknown structure)
60%: C06 (Biotechnology, plant genetics, veterinary vaccines)
UNIV ILLINOIS 10 0.5% 100%: D16 (Fermentation industry)
70%: B04 (Natural products and polymers, testing, compounds of unknown structure)
40%: E17 (Other aliphatics)
UNIV KYOTO 10 0.5% 90%: D16 (Fermentation industry)
50%: B04 (Natural products and polymers, testing, compounds of unknown structure)
30%: S03 (Scientiﬁc Instrumentation, photometry, calorimetry)
UNIV KYUSHU 10 0.5% 100%: D16 (Fermentation industry)
60%: B04 (Natural products and polymers, testing, compounds of unknown structure)
40%: S03 (Scientiﬁc Instrumentation, photometry, calorimetry)
HARVARD UNIV 9 0.4% 89%: D16 (Fermentation industry)
89%: B04 (Natural products and polymers, testing, compounds of unknown structure)
44%: C06 (Biotechnology, plant genetics, veterinary vaccines)
Source: own calculation based on the Derwent Innovation Index (DII). N=2,118 patent families with application years= 1993-2016. A patent
may be classiﬁed in more than one Derwent Class, thus totals exceed 100%.
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covered areas of the chemical space by the set of
reachable compounds and the ones in patent docu-
ments. This representation is based on chemical
descriptors, as described in supporting information, and
it is generally used to analyse a set of compounds in
terms of their chemical similarity. Interestingly, we
observed that patent compounds tend to appear clus-
tered at some speciﬁc regions, whereas other areas of
the reachable space still remain basically under-
explored. One of the factors that may be associated with
areas of lesser coverage is pathway length, as we previ-
ously discussed. Pathway length is arguably one of the
most important limiting factors for heterologous pathway
expression. As shown in Fig. 3B, when we added a third
dimension that considered pathway length to the plot,
we see that a considerable number of pathways that did
not appear in patents (blue dots) belong to pathways
involving multiple steps.
We further analysed the organizations and the targets
involved in the patenting of synthetic biology for ﬁne
chemical production by linking our chemical pathways
database to the Derwent Innovation Index Database.
This analysis focused on patent families each of which
can contain multiple patent documents (see Data S1 for
more details). We ﬁnd modest levels of patenting of ﬁne
chemical production pathways in the 1990s, with some
tail-off in the early 2000s. From the late 2000s, however,
there was a rapid growth in the number of patent appli-
cations identiﬁed in Derwent, peaking at around 500
patents per year in recent periods (Fig. S4). Based on
Derwent patent classes, the vast majority of patents
(more than 90%) are classed in fermentation sectors,
while natural products and polymers in pharmaceuticals
(around 52%), biotechnology, plant genetics, veterinary
vaccines (22%) and scientiﬁc instrumentation (around
14%) are the other leading classes (Table 2). While fer-
mentation classiﬁcations have been maintained at high
levels the past three decades, biotechnology in agricul-
tural chemicals increased modestly and natural products
and polymers decreased signiﬁcantly (Fig. 4).
The leading patent assignees in our dataset com-
prise large commercial conglomerates active in a
range of industries. No single organizations held more
than 5% of our patent dataset. There is an evident
specialization in terms of application areas by Derwent
classes. While almost all leading ﬁrms have patents in
fermentation sectors, companies with strong chemical
industry capabilities such as Du Pont, BASF, Bayer as
well as ﬁrms operating mainly in agri-food such as Aji-
nomoto and Monsanto patented in the general cate-
gory of “biotechnology, plant genetics, and veterinary
vaccines.” On the other hand, a number of leading
ﬁrms specialized in other applications areas; for
instance, Butamax focused on fuels, Goodyear
patented on monomers and condensants while natural
products and polymers were targeted by Mitsui and
Mitsubishi (Table 3). Universities, government and
other research labs are also active in patenting
through synthetic biology pathways. As with commer-
cial organizations, most applications fall into fermenta-
tion, natural products and polymer classiﬁcations
(Table 4).
These results present a novel way to develop new
perspectives on the patenting landscape of synthetic
biology, in this case focused on biosynthetic pathways
for ﬁne and speciality chemicals. The approach provides
valuable information that can help in the design process,
as it can serve to select targets of interest as well as to
deﬁne criteria for enzyme selection in designated path-
ways in chassis organisms. Ultimately, these data may
serve to develop machine-learning approaches to predict
best target compounds and enzymes according to inno-
vation criteria. There are synthetic biology applications
that have not been fully covered in this patent study, as
long as they are not directly related to biosynthetic path-
ways. Our approach can be extended to the screening
of other synthetic biology-relevant sequences such as
those deposited at public registries of biological parts,
extending in that way the study to other genetic parts of
synthetic biology devices and systems, such as
regulatory and sensing components.
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